LA JOLLA CANCER RES FOUNDATION has a total of 14 patent applications. Its first patent ever was published in 1989. It filed its patents most often in Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SHANGHAI INST OF IMMUNOLOGY, UNIV ZURICH and PIERIS PHARMACEUTICALS GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 14 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Medical technology |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials | |
#5 | Microorganisms | |
#6 | Object sterilising | |
#7 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Ruoslahti Erkki I | 6 |
#2 | Vogel Bruce E | 3 |
#3 | Engvall Eva | 2 |
#4 | Tarone Guido | 2 |
#5 | Pierschbacher Michael D | 2 |
#6 | Giancotti Filippo G | 2 |
#7 | Border Wayne A | 1 |
#8 | Harper John R | 1 |
#9 | Vuori Kristiina | 1 |
#10 | Leivo Ilmo | 1 |
Publication | Filing date | Title |
---|---|---|
AU4111893A | Methods for treating vascular disorders by inhibiting the endothelin stimulatory activity of TGFbeta | |
AU8946991A | Method of inhibiting transcription utilizing nuclear receptors | |
AU7334291A | Merosin, nucleic acids encoding, fragments and uses thereof | |
AU3865389A | Suppression of cell proliferation by decorin |